瘤微环境通过HGF分泌引起对RAF抑制剂的先天性耐药性
Ravid Straussman1, Teppei Morikawa, Kevin Shee
1The Eli and Edythe L. Broad Institute, 7 Cambridge Center, Cambridge, Massachusetts 02142, USA.
Nature
|July 6, 2012
概括
瘤微环境,而不仅仅是癌细胞,导致耐药性. 流体细胞分泌诸如肝细胞生长因子 (HGF) 等阻断癌症药物有效性的因素,这表明针对癌症和流体细胞的组合疗法.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 瘤微环境研究 研究
背景情况:
- 癌症患者的耐药性是一个重大的临床挑战.
- 大多数研究都侧重于癌细胞内在的抵抗机制.
- 人们越来越认识到瘤微环境在赋予先天性耐药性的作用.
研究的目的:
- 为了研究各种树皮细胞类型对癌细胞耐药性的影响.
- 确定瘤微环境中介于抗癌药物耐药性的特定机制.
- 探索新的治疗策略,以克服通过肌介导的耐药性.
主要方法:
- 开发一种共同培养系统,测试23种树皮细胞类型与45种癌细胞系和35种药物对抗.
- 蛋白质组分析以确定抵抗的分子媒介.
- 免疫组织化学验证患者样本中的发现.
- 抑制研究以评估治疗潜力.
主要成果:
- 流体细胞通常会赋予抗癌药物,特别是向药物的先天性耐药性.
- 脑膜细胞分泌的肝细胞生长因子 (HGF) 激活MET,重新激活MAPK和PI(3) K-AKT通路,导致BRAF突变黑色素瘤中RAF抑制剂的立即耐药性.
- 流体HGF表达与患者对RAF抑制剂的先天性耐药性相关.
- 在BRAF突变结直肠和质母细胞瘤细胞系中观察到类似的耐药机制.
结论:
- 瘤微环境在调解先天性抗药性方面发挥着至关重要的作用.
- 针对像HGF或其受体MET这样的结构因子,结合RAF抑制剂,可以克服BRAF突变黑色素瘤的耐药性.
- 对瘤-肌瘤相互作用的系统分析对于发现耐药性机制和开发有效的癌症疗法至关重要.
更多相关视频
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
06:44Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells
Published on: March 1, 2024
相关概念视频
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Small GTPases - Ras and Rho
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
